Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nanoengineered approaches to improve the efficacy of targeted drug delivery for the treatment of malignancy: a comprehensive review
Future Journal of Pharmaceutical Sciences Open Access 16 October 2023
-
Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model
Cancer Cell International Open Access 27 December 2022
-
Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy
Journal of Nanobiotechnology Open Access 14 June 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Hughes, B. Antibody–drug conjugates for cancer: poised to deliver?. Nat Rev Drug Discov 9, 665–667 (2010). https://doi.org/10.1038/nrd3270
Issue Date:
DOI: https://doi.org/10.1038/nrd3270
This article is cited by
-
Nanoengineered approaches to improve the efficacy of targeted drug delivery for the treatment of malignancy: a comprehensive review
Future Journal of Pharmaceutical Sciences (2023)
-
Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy
Journal of Nanobiotechnology (2022)
-
Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model
Cancer Cell International (2022)
-
Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
Biomaterials Research (2021)
-
Fate of Antibody-Drug Conjugates in Cancer Cells
Journal of Experimental & Clinical Cancer Research (2018)